Angelini Pharma – An overview of the US pharma landscape

12

BACKGROUND
Over the past 10+ years the pharmaceutical Industry has utilized CDMO’s at an increasing level from year to year never seen prior to this period. The reasons are multidimensional involving a combination of new complex molecules for drug therapies such as NASH, antivirals (e.g. Hepatitis and most recently CoVID) as well as the ever expanding Oncology sector, all with small molecules being still dominant.